Aspire-Lakewood vs Gelteq
ASBP and GELS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ASBP and GELS compare
Aspire-Lakewood scores higher on the StockData Score (2 against 0 for Gelteq), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ASBP | GELS |
|---|---|---|
| Size and price | ||
| Market cap | $11.8M | – |
| Share price | $8.41 | $0.380 |
| Change, 1 year | 95.9% | −64.1% |
| Beta (5Y) | – | 2.50 |
| StockData Score | ||
| Total score | 2 (better) | 0 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 1 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 121× | – |
| P/B | 1.0× | – |
| Profitability | ||
| Gross margin | −25.0% | 30.3% (better) |
| Operating margin | −7495% | −3318% (better) |
| Net margin | −11314% | – |
| FCF margin | – | −3335% |
| Return on equity | −1032% | – |
| Financial health | ||
| Interest coverage | −0.8× (better) | −2.8× |
| Current ratio | 7.99 (better) | 0.09 |
| Altman Z-score | −0.05 | – |
| Piotroski F-score | 3 | – |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by insiders | 1.4% | 14.0% |
Go deeper
- ASBP stock overview
- ASBP income statement
- ASBP valuation and score
- GELS stock overview
- GELS income statement
- GELS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.